Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Pulmonary Arterial Hypertension (PAH)
NCT07140484Phase 4Recruiting
- Sponsor
- University of Alberta
- Start
- Oct 2025
- Primary completion
- Jan 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by University of Alberta. Started Oct 2025; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07140484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07140484.